Gavreto net present value: $5/share for NSCLC and MTC (Jefferies) - Aug 31, 2022 - A subscription to REFINITIVE is required to access document 98050114 | Page no: 02 | REPORT TITLE: "Expert call on Ph2 pioneer data for Ayvakit" | AUTHOR: Eun K. Yang, PHD, et al | DATE: 08/22/22
Commercial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Thyroid Gland Medullary Carcinoma
|
|
If you have access to Aftermarket Research from Refinitiv, please log in to your account using this link and enter report number or title to find the report. If you don’t have access but would like to purchase the report please contact OnDemand@refinitiv.com.
|